drug ineffective; sars-cov-2 infection; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority and product quality. the reporter is the patient. a 28 year-old female patient (not pregnant) received bnt162b2 (comirnaty), administration date 16jan2022 (lot number: fn5254) as dose 3 (booster), single, (batch/lot number: unknown) as dose 1, single and (batch/lot number: unknown) as dose 2, single for covid-19 immunisation. the patient had no relevant medical history. the patient's concomitant medications were not reported. the following information was reported: covid-19 (disability, medically significant) with onset 11feb2022, outcome "recovered" (18feb2022), described as "sars-cov-2 infection"; drug ineffective (disability, medically significant), outcome "unknown", described as "drug ineffective". the events "sars-cov-2 infection" and "drug ineffective" were evaluated at the physician office visit. the patient underwent the following laboratory tests and procedures: sars-cov-2 test: (11feb2022) positive, notes: yes - positive covid-19 test. clinical course patient was not currently breastfeeding. patient stated that the day after she had her vaccine she started with a very concentrated ache on the left side of her chest. over the past month it was getting more prominent and she was now getting shooting pains. patient was not enrolled in clinical trial she said she had seen her gp who had listen to her heart and checked vitals. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected.; sender's comments: linked report(s) : gb-pfizer inc-202200315385 same patient different dose different event

test date: 20220211; test name: covid-19 virus test; result unstructured data: test result:positive; comments: yes - positive covid-19 test

na

na